The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib.
Posted by rob on January 27, 2006 under Uncategorized | 
Be the First to Comment
Haematologica. 2006 Jan ; 91(1): 137-8
Imatinib mesylate has become the gold standard front-line treatment of chronic myelogenous leukemia through its ability to inhibit ABL tyrosyne kinase. Resistance to this inhibition may occur. We investigated the role of the K247R polymorphism in persistent sensitivity.
The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib.
Add A Comment
You must be logged in to post a comment.